


PRIORITIZING CUSTOMER UPTIME

DON'T LET SUPPLY DISRUPTIONS STOP YOUR VALIDATED PROCESS

For the biopharmaceutical industry, one of the key operational learnings from the COVID-19 pandemic was the vulnerability of proprietary, single-sourced consumables. This was especially prevalent in single-use bioprocessing, with some supplier lead times for bags stretching as much as 12 months.¹ For validated processes that cannot simply switch bags without significant requalification, the only alternative for customers was to wait.

According to a BioPlan Associates survey, single-use supply shortfalls were among top concerns for respondents. These supply chain vulnerabilities are expected to grow as bioprocessing continues to adopt single-use.

INDUSTRY LEAD TIMES VS. ABEC CSR



Despite the surge in order volume during the pandemic and continuing after, ABEC CSR's lead time for DCs (disposable containers) has held steady approximately 16 weeks from time of order to delivery. ABEC reduced the risk of disruptions and delays to our customers by building a resilient infrastructure, including:

- **Reserve capacity** - no risk of supply constraints during demand surges
- **In-house manufacturing** - no 3rd party assemblers whose allocation priorities may shift
- **Multiple qualified sources** - no over-reliance on a single supplier
- **Non-proprietary materials** - no single-point of supply failure

<https://www.bioprocessonline.com/doc/the-single-use-bioprocessing-bottleneck-looking-ahead-0001>